Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17529572 | 0.85 | CYP2C9 (0.53) | CYP2C9CYP1A2EPHX1HIF1A | |
| SCHEMBL6533548 | 0.82 | CYP2C9 (1.00) | CYP2C9CYP1A2ALDH1A1 | |
| SCHEMBL2534752 | 0.82 | CYP2C9 (0.84) | CYP2C9CYP1A2ALDH1A1 | |
| SCHEMBL3422484 | 0.78 | CYP2C9 (0.89) | CYP2C9CYP1A2ALDH1A1 | |
| SCHEMBL14064577 | 0.75 | ALDH1A1 (0.45) | CYP2C9CYP1A2ALDH1A1 | |
| SCHEMBL2049555 | 0.73 | EPHX1 (0.67) | CYP2C9CYP1A2EPHX1HIF1AALDH1A1 | |
| SCHEMBL1821144 | 0.72 | CYP2C9 (0.42) | CYP2C9CYP1A2HPGDALOX15 | |
| SCHEMBL8716044 | 0.72 | CYP2C9 (0.39) | CYP2C9HPGDALOX15 | |
| SCHEMBL14064581 | 0.72 | CYP2C9 (0.40) | CYP2C9HPGDALOX15 | |
| SCHEMBL18905783 | 0.71 | CYP2C9 (0.38) | CYP2C9HPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2566845-B1 | CONJUGATION REACTIONS | INNOVA BIOSCIENCES LTD (GB) | 2017-05-24 | — | — | EP | claimed |
| US-8877892-B2 | Conjugation reactions | INNOVA BIOSCIENCES LIMITED (GB) | 2014-11-04 | — | — | US | claimed |
| EP-2123328-B1 | Galanthamine derivatives, methods for their obtaining and use | SOPHARMA AD (BG) | 2011-05-04 | — | — | EP | claimed |
| EP-2123328-A1 | Galanthamine derivatives, methods for their obtaining and use | Sopharma AD (BG) | 2009-11-25 | — | — | EP | claimed |
| EP-0611774-B1 | Production of amides and peptides without racemization in the presence of catalytic amounts of a N-hydroxy-compound | HOFFMANN LA ROCHE (CH) | 1999-05-26 | — | — | EP | claimed |
| EP-4655073-A2 | CEREBLON-BASED KRAS DEGRADING PROTACS ANS USES RELATED THERETO | Arvinas Operations, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12448399-B2 | Cereblon-based KRAS degrading PROTACs and uses related thereto | ARVINAS OPERATIONS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| WO-2024159164-A2 | CEREBLON-BASED KRAS DEGRADING PROTACS ANS USES RELATED THERETO | ARVINAS OPERATIONS, INC. (US) | 2024-08-02 | — | — | WO | disclosed |
| WO-2023230604-A2 | METHODS OF PREPARING RNA SAMPLES FOR SEQUENCING, METHODS OF SEQUENCING RNA, AND METHODS OF PREPARING RNA MOLECULES WITH MODIFIED MUCLEIC ACIDS | THOMAS JEFFERSON UNIVERSITY (US) | 2023-11-30 | — | — | WO | disclosed |
| US-11782062-B2 | Kits for analysis using nucleic acid encoding and/or label | Encodia, Inc. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11782062-B2 | Kits for analysis using nucleic acid encoding and/or label | Encodia, Inc. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230220589-A1 | POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF | Encodia, Inc. (US) | 2023-07-13 | — | — | US | disclosed |
| EP-0031722-B1 | WATER SOLUBLE GUANIDINE DERIVATIVES OF POLYENE MACROLIDES AND THE ESTERS THEREOF, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | A/S Dumex (Dumex Ltd.) (DK) | 1984-03-28 | — | — | EP | disclosed |
| EP-0004512-B1 | MURAMYL-PEPTIDE ESTER DERIVATIVES AND THEIR APPLICATION TO PHARMACOLOGICAL COMPOSITIONS AND LABORATORY REACTANTS | ANVAR Agence Nationale de Valorisation de la Recherche (FR) | 1984-01-18 | — | — | EP | disclosed |
| US-4396607-A | IMMUNOLOGY, ANTIGENS | AGENCE NATIONALE DE VALORISATION DE LA RECHERCHE (ANVAR) (FR) | 1983-08-02 | — | — | US | disclosed |
| US-4351902-A | Production of 2-keto-D-gluconic acid and hydrogen peroxide | CETUS CORPORATION (US) | 1982-09-28 | — | — | US | disclosed |
| US-4284723-A | HALOHYDRIN FORMATION WITH HALOGENATING ENZYME, OXIDIZER, HALIDE ION | CETUS CORPORATION (US) | 1981-08-18 | — | — | US | disclosed |
| US-4247641-A | USING A HALOGENATING ENZYME, AN OXIDIZER, AND A HALIDE ION SOURCE TO OBTAIN THE HALOHYDRIN INTERMEDIATE | CETUS CORPORATION (US) | 1981-01-27 | — | — | US | disclosed |
| WO-1979000802-A1 | NEW ESTER COMPOUNDS OF MURAMYL-PEPTIDE AND APPLICATIONS THEREOF TO PHARMACEUTICAL COMPOSITIONS AND LABORATORY REACTA | ANVAR (FR) | 1979-10-18 | — | — | WO | disclosed |
| EP-0004512-A1 | Muramyl-peptide ester derivatives and their application to pharmacological compositions and laboratory reactants | ANVAR Agence Nationale de Valorisation de la Recherche (FR) | 1979-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448399-B2 | Cereblon-based KRAS degrading PROTACs and uses related thereto | CRBN, KRAS, WEE1 | CYP2C9 4176/4885CYP1A2 4381/4885EPHX1 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.